Navigation Links
Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
Date:1/29/2008

TORONTO, Jan. 29 /PRNewswire/ - Viventia Biotech Inc., a privately held biopharmaceutical company advancing a portfolio of novel antibody therapeutics focused on cancer, announced today it intends to explore strategic alternatives to further advance and realize value from its pipeline of therapeutic antibodies, its antibody discovery platform and its antibody manufacturing capabilities. The Company will consider potential strategic opportunities including, but not limited to, the sale or merger of the Company with another entity, and has retained HSBC to act as advisors in this process.

The Company also provided an update on the clinical development programs for Proxinium(TM) (Phase 3), Vicinium(TM) (Phase 2) and VB6-845 (Phase 1). Proxinium(TM) is undergoing a global pivotal Phase 3 trial (the 'TARGET' trial) in approximately 300 patients with advanced head and neck cancer. Viventia recently completed an interim efficacy assessment on the study's primary endpoint of median survival. These preliminary results demonstrated a clear survival advantage in the Proxinium(TM) arm.

"We have successfully advanced three antibody programs into clinical trials, and are about twelve months from expected final efficacy data for our pivotal Phase 3 TARGET trial of Proxinium(TM). We believe that our recently performed interim efficacy analysis of survival data from TARGET strongly supports the future prospects for this drug. In addition to our clinical programs, we have generated a broad pipeline from our antibody discovery platform, which has yielded a number of compelling novel targets, including several that have expression profiles consistent with cancer stem cells, an exciting new area of cancer research," said Dr. Nick Glover, President and CEO of Viventia Biotech. "We believe it is important to explore all options to ensure adequate resources are available for the advancement of our products through to commercialization and to further recognize the value
'/>"/>

SOURCE Viventia Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... and Trademark Office (PTO) has issued a patent related ... weight loss. NB32 is a fixed-dose combination of naltrexone ... Patent No. 8,815,889 claims methods for treating insulin resistance ... expires in 2024. If NB32 is approved for use ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... BETHESDA, Md. , Sept. 2, 2014  Spherix ... fostering and monetization of intellectual property, today announced that ... three patents to the Company in the month of ... of patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and ...
(Date:9/1/2014)... , Sept. 1, 2014 Reportlinker.com ... available in its catalogue: India Solid ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... are the main governing bodies responsible for complete ... cities. On an average, around 135,000 MT solid ...
Breaking Biology Technology:Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Switzerland, October 5, 2011 Debiopharm Group™ ... on drug development and companion diagnostics, today presented the ... Cancer Center Research Institute in Tokyo, for his basic ... genes, and to Doctor Mineo Kurokawa from the University ...
... 4, 2011 The VENTANA anti-Helicobacter pylori (SP48) Rabbit ... H. pylori antibody to receive 510(k) ... by Ventana Medical Systems, Inc. (Ventana), a member of ... used in immunohistochemical (IHC) staining, aids in the detection ...
... JACKSONVILLE, Fla., Oct. 4, 2011 MSC Care ... and services to post-discharge and post-injury workers, compensation ... Integrated Healthcare Services, a national company also focused ... unique and comprehensive surgical implant cost management solution, ...
Cached Biology Technology:The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 2The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 3Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 2Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 3MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services 2
(Date:9/2/2014)... From AGU,s blogs: Earthquake rupture through a U.S. suburb ... University of California Davis in the hours and days ... helping scientists understand why the earthquake caused so much ... The Trembling Earth blog, hosted by the American Geophysical ... Future Mars Rovers: The Next Places to Direct Our ...
(Date:9/2/2014)... September 3, The Field Museum will present the prestigious ... of his commitment to biodiversity conservation awareness. The Parker/Gentry ... an outstanding individual, team or organization whose efforts have ... natural heritage and whose actions can serve as a ... of Mongabay.com, an environmental science and conservation news website ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... to support the theory that old cells help make ... that as these animals age, the number of aging ... cells lose their ability to divide, a state known ... advanced online edition of Science, is the first to ...
... the journal Genome Research that large segments ... mobile DNA elements called transposons. The locations of ... are enriched in genes crucial for the regulation of ... DNA sequences that have the capacity to move from ...
... SIDS (sudden infant death syndrome) in African Americans can be ... deaths result from a common genetic variation that increases an ... of environmental stress, a research team based at the University ... Journal of Clinical Investigation. , Children with two copies ...
Cached Biology News:Aging cells, aging body: Fresh evidence for a connection 2Where 'jumping genes' fear to tread 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3